JP6112867B2 - サキシトキシン誘導体での触覚の喪失の処置 - Google Patents

サキシトキシン誘導体での触覚の喪失の処置 Download PDF

Info

Publication number
JP6112867B2
JP6112867B2 JP2012552401A JP2012552401A JP6112867B2 JP 6112867 B2 JP6112867 B2 JP 6112867B2 JP 2012552401 A JP2012552401 A JP 2012552401A JP 2012552401 A JP2012552401 A JP 2012552401A JP 6112867 B2 JP6112867 B2 JP 6112867B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sodium channel
channel blocker
gtx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012552401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519653A5 (enExample
JP2013519653A (ja
Inventor
ルットマン，マックス
ジャック ピロルジェ，ジャン
ジャック ピロルジェ，ジャン
シガ−ラ，コンスタンツァ
ヴァレンツェラ，パブロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytotox Ltd
Original Assignee
Phytotox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox Ltd filed Critical Phytotox Ltd
Publication of JP2013519653A publication Critical patent/JP2013519653A/ja
Publication of JP2013519653A5 publication Critical patent/JP2013519653A5/ja
Application granted granted Critical
Publication of JP6112867B2 publication Critical patent/JP6112867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012552401A 2010-02-10 2011-02-10 サキシトキシン誘導体での触覚の喪失の処置 Active JP6112867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153234 2010-02-10
EP10153234.9 2010-02-10
US31290310P 2010-03-11 2010-03-11
US61/312,903 2010-03-11
PCT/EP2011/051992 WO2011098539A1 (en) 2010-02-10 2011-02-10 Treatment of loss of sense of touch with saxitoxin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016217143A Division JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Publications (3)

Publication Number Publication Date
JP2013519653A JP2013519653A (ja) 2013-05-30
JP2013519653A5 JP2013519653A5 (enExample) 2014-03-13
JP6112867B2 true JP6112867B2 (ja) 2017-04-12

Family

ID=43828310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012552401A Active JP6112867B2 (ja) 2010-02-10 2011-02-10 サキシトキシン誘導体での触覚の喪失の処置
JP2016217143A Pending JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016217143A Pending JP2017081920A (ja) 2010-02-10 2016-11-07 サキシトキシン誘導体での触覚の喪失の処置

Country Status (6)

Country Link
US (2) US9107925B2 (enExample)
EP (1) EP2533785B1 (enExample)
JP (2) JP6112867B2 (enExample)
CN (1) CN102811722A (enExample)
ES (1) ES2484315T3 (enExample)
WO (1) WO2011098539A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017081920A (ja) * 2010-02-10 2017-05-18 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2638908A1 (en) * 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
RU2015143665A (ru) * 2013-03-15 2017-04-27 Дзе Чилдрен'З Медикал Сентер Корпорейшн Сочетанные препараты неосакситоксина для пролонгированной местной анестезии
EP3129381B1 (en) * 2014-04-09 2020-11-04 Siteone Therapeutics Inc. 10',11'-modified saxitoxins useful for the treatment of pain
AU2016329201A1 (en) * 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process
AU2018243463C1 (en) 2017-03-29 2022-12-01 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
IL300626A (en) * 2020-08-14 2023-04-01 Siteone Therapeutics Inc Ketone-free inhibitors of NAV1.7 for the treatment of pain
WO2022112887A1 (en) * 2020-11-25 2022-06-02 Algenis Method of treating acute nociceptive pain in mammals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
ES2401570T3 (es) 2001-11-15 2013-04-22 Phytotox Limited Composiciones farmacéuticas que contienen 3,4-propinoperhidropurinas y usos de las mismas para bloquear la transmisión neuronal
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
JP5047782B2 (ja) 2004-05-07 2012-10-10 ファイトトックス リミテッド フィコトキシン及びその使用
AU2005287511A1 (en) * 2004-09-21 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017081920A (ja) * 2010-02-10 2017-05-18 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置

Also Published As

Publication number Publication date
US20130039976A1 (en) 2013-02-14
EP2533785B1 (en) 2014-04-23
CN102811722A (zh) 2012-12-05
JP2017081920A (ja) 2017-05-18
US9107925B2 (en) 2015-08-18
ES2484315T3 (es) 2014-08-11
US20160000793A1 (en) 2016-01-07
WO2011098539A1 (en) 2011-08-18
JP2013519653A (ja) 2013-05-30
EP2533785A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
CN105142625B (zh) 用于长效局部麻醉的新蛤蚌毒素组合配制品
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2018005695A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
EP4114466B1 (en) Treatment of pain and vasoconstriction
EP2720699A2 (en) Administration of benzodiazepine
US20170119794A1 (en) Treatments of accumulated fat with deoxycholic acid and salts thereof
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
EP2059259A1 (en) Pharmaceutical compositions for the treatment of fungal infections
RU2633637C2 (ru) Паралитический яд моллюсков
WO2005060957A1 (en) Formulation of nefopam and its use in the treatment of pain
AU2012244095A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual
WO2017062837A1 (en) Treatment of skin disorders by topical administration of vegf inhibitors
JPH061721A (ja) 疼痛処置剤、及び疼痛軽減作用増強剤
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
HK1179530B (en) Treatment of loss of sense of touch with saxitoxin derivatives
HK1179530A (en) Treatment of loss of sense of touch with saxitoxin derivatives
WO2023034568A1 (en) Specific therapeutic medical marijuana doses for stress and pain
WO2008106738A1 (en) Compositions for the treatment of sexual dysfunction
EA049826B1 (ru) Комбинация лекарственных средств в парентеральной лекарственной форме для длительной анестезии
HK1174049A (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
RU2011106753A (ru) Способы введения топических противогрибковых препаратов для лечения грибковых инфекций
HK1218384B (zh) 用於長效局部麻醉的新蛤蚌毒素組合配製品
HK1205934B (en) Paralytic shellfish poison for the treatment of itch

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170314

R150 Certificate of patent or registration of utility model

Ref document number: 6112867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250